Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography

Completed

Conditions studied: Crohn's Disease

In brief

Anti-TNF therapy induces intestinal wall remodeling that correlates with clinical response and can be detected in patients undergoing serial computed tomography enterography (CTE).

Key facts

Study ID

NCT00819663

Run by

Mayo Clinic

People needed

67

Starts

2009-02-01

Expected to finish

2010-08-01

Last updated by the study team

2011-08-19

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Established Crohn's disease
• CTE before and after initiating infliximab
• Underwent at least 2 CTEs between 1/1/2004 and 12/31/2007
• At least 6 months between CTEs
• off-label use of infliximab by either increased dose or shortened interval will be included in the study Exclusion criteria
• Small bowel surgery occurring before repeat CTE imaging
• Episodic infliximab therapy (intervals greater than every 8 weeks)

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.